Want to see ADAPY full AI Analyst Report?
Adaptimmune Therapeutics (ADAPY) AI Stock Analysis
Adaptimmune Therapeutics
(Other OTC:ADAPY)
The very low overall score reflects severe financial strain—shrinking revenue, negative equity, and heavy cash burn—combined with a pronounced downward price trend and only limited oversold indications, while traditional valuation metrics offer no offsetting strength given the ongoing losses and lack of dividend.
Adaptimmune Therapeutics (ADAPY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.46M
- Dividend Yield
- ―
- Average Volume (3M)
- 191.08K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- -7.98
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 272
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Adaptimmune Therapeutics Business Overview & Revenue Model
Company Description
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as...
How the Company Makes Money
Adaptimmune Therapeutics generates revenue primarily through collaborations and partnerships with pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future sales of therapies developed in partnership. T...
Adaptimmune Therapeutics Earnings Call Summary
Adaptimmune reported a very successful launch of TECELRA with strong initial sales and effective patient access. The early activation of treatment centers and manufacturing success further support their positive outlook. However, financial challenges remain with doubts about their ability to continue as a going concern.
Q1-2025 Updates
Positive Updates
Negative Updates
Company Guidance
In the first quarter of 2025, Adaptimmune reported significant progress in the launch of TECELRA, with 21 patients apheresed to date, including 13 in Q1 and 8 in early Q2. The company provided revenue guidance for the full year, anticipating TECELRA sales of $35 million to $45 million. Adaptimmune reported invoicing 14 TECELRA treatments in 2025, including 6 in Q1, resulting in $4 million in net sales, and 8 additional invoiced treatments early in Q2. The company achieved 100% manufacturing success, with an average turnaround from apheresis to lot release of 27 days, surpassing the 30-day target. Adaptimmune's network includes 28 active treatment centers, with expectations to reach 30 by year-end, a year ahead of schedule. No patient access issues have been reported, with no denials to date. Adaptimmune foresees peak sales of $400 million from its TECELRA and lete-cel sarcoma franchise, with lete-cel launch activities underway, targeting a 2026 approval.
Adaptimmune Therapeutics Financial Statement Overview
Summary
Financial performance is extremely weak: revenues have fallen sharply (~-63.8% TTM), equity is now negative, margins are deeply negative at EBIT/EBITDA and net levels, and free cash flow and operating cash flow remain heavily negative, indicating ongoing losses, balance sheet stress, and elevated liquidity risk.
Income Statement
18Very NegativeBalance Sheet
8Very NegativeCash Flow
11Very Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.08M | 178.03M | 60.28M | 27.15M | 6.15M | 3.96M |
| Gross Profit | 61.70M | 177.96M | 50.42M | -100.58M | -104.94M | -87.61M |
| EBITDA | -149.75M | -52.66M | -128.59M | -155.59M | -155.68M | -125.81M |
| Net Income | -169.76M | -70.81M | -113.87M | -165.46M | -158.09M | -130.09M |
Balance Sheet | ||||||
| Total Assets | 130.63M | 245.96M | 282.62M | 328.92M | 469.55M | 451.14M |
| Cash, Cash Equivalents and Short-Term Investments | 26.06M | 151.60M | 146.94M | 204.60M | 369.58M | 368.22M |
| Total Debt | 48.68M | 74.21M | 25.23M | 23.08M | 25.47M | 23.71M |
| Total Liabilities | 201.59M | 234.11M | 243.10M | 247.04M | 263.58M | 109.92M |
| Stockholders Equity | -70.96M | 11.85M | 39.51M | 81.88M | 205.96M | 341.23M |
Cash Flow | ||||||
| Free Cash Flow | -191.71M | -75.93M | -145.76M | -171.51M | 1.95M | -56.50M |
| Operating Cash Flow | -190.03M | -73.21M | -140.88M | -141.77M | 10.73M | -53.59M |
| Investing Cash Flow | 1.79M | -58.95M | 176.54M | 89.14M | 75.80M | -278.92M |
| Financing Cash Flow | 1.34M | 78.75M | 880.00K | 12.87M | 3.29M | 340.05M |
Adaptimmune Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADAPY, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bullish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 51.25 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADAPY.
Adaptimmune Therapeutics Risk Analysis
Adaptimmune Therapeutics disclosed 82 risk factors in its most recent earnings report. Adaptimmune Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksAdaptimmune Therapeutics Peers Comparison
Overall Rating
BCAB45Neutral
XLO44Neutral
SNTI41Neutral- ADAPY40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BCAB | 45Neutral | $3.50M | -0.07 | 89.25% | ― | -22.73% | 53.53% |
| XLO | 44Neutral | $52.84M | -5.36 | -50.77% | ― | 327.25% | 85.65% |
| SNTI | 41Neutral | $5.14M | -0.11 | -1539.97% | ― | ― | 80.28% |
| ADAPY | 40Underperform | $6.10M | -0.07 | 115.05% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ADAPY | Adaptimmune Therapeutics Plc. | 0.03 | -0.02 | -36.59% | |
| BCAB | Bioatla, Inc. | 2.06 | -31.61 | -93.88% | |
| SNTI | Senti Biosciences, Inc. | 0.19 | -1.62 | -89.61% | |
| XLO | Xilio Therapeutics Inc | 7.99 | -3.23 | -28.82% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 25, 2025